As you consider your treatment goals for your relapsing MS patients— now and in years to come—you can count on Teva and COPAXONE®.
Teva's Shared Solutions® can take care of many important behind-the-scenes details so you can focus on treating your patients.VIEW SUPPORT SERVICES
Teva is committed to helping your patients find financial solutions to start and stay on COPAXONE® treatment. Teva's Shared Solutions® offers a range of services to help COPAXONE® 40 mg/mL patients gain access to therapy. A $0 monthly co-pay is available for eligible patients.*
Call on Shared Solutions® and Teva Field Nursing to be your partners for patient training, education, and support for Teva products. Our nationwide team is dedicated to supporting COPAXONE® patient compliance and care.NURSING SUPPORT
In a 3-times-a-week COPAXONE® 40 mg/mL clinical trial,1 91% of patients treated with COPAXONE® 40 mg/mL stayed on therapy for over 12 months. Approximately 3% of patients treated with COPAXONE® 40 mg/mL discontinued treatment due to an adverse event.
An immunoactive mixture of synthesized polypeptides, COPAXONE® is thought to work by modifying immune processes that are believed to be responsible for the pathogenesis of RMS. The mechanism(s) by which COPAXONE® exerts its effect in patients with RMS are not fully understood. COPAXONE® can modify immune functions, and concerns exist about its potential to alter naturally-occurring immune responses. There is no evidence that COPAXONE® does this, but this has not been systematically evaluated.1,2,3SEE DETAILS
Our history of innovation continued with the approval of
3-times-a-week COPAXONE® 40 mg/mL in 2014, giving relapsing MS patients the option of 208 fewer injections per year compared with daily COPAXONE® 20 mg/mL.
COPAXONE® is an immunoactive mixture of synthesized polypeptides consisting of four naturally occurring amino acids.
Teva rigorously tested COPAXONE® in 5 clinical trials between 1987 and 2013, demonstrating it to be an effective, safe, and tolerable choice for relapsing MS treatment.VIEW TRIALS
The first-of-its-kind support program for the MS community, Teva's Shared Solutions® began in 1997. The program has evolved over the years to include personalized and innovative services and tools for Teva's COPAXONE® patients and healthcare practices.SEE PROGRAM OFFERINGS
In the 1960s, Drs. Michael Sela and Ruth Arnon of the Weizmann Institute of Science in Rehovot, Israel, discovered copolymer 1 (now known as COPAXONE®).4 They went on to study its effectiveness in suppressing MS-like disease in animal models. The development of COPAXONE® continued through the 1970s and 1990s,4-6 and it was approved for RRMS in 1996.1
Injections for 3-times-a-week COPAXONE® 40 mg must be at least 48 hours apart.
COPAXONE® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.
Approximately 16% of patients exposed to COPAXONE® 20 mg per mL compared to 4% of those on placebo, and approximately 2% of
The website you are about to visit does not belong to Teva Neuroscience, Inc. or follow the same terms of service. Some of these websites may also require a third-party account, subscription, or payment to view.
While we carefully choose which websites we link to, we cannot control any changes or actions made by them. As a result, Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of the following site, nor any liability on their behalf.